{
  "id": 20932214,
  "title": "Walmart Gets Bullish Rating Despite Pharmacy Deflation Headwinds",
  "url": "https://urgent.news/2026/11/20/walmart-gets-bullish-rating-despite-pharmacy-deflation-headwinds",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T18:19:31.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/11/63495713/walmart-gets-bullish-rating-despite-pharmacy-deflation-headwinds"
  },
  "original_language": "en",
  "account": "Walmart Inc.'s stock is on the rise on Friday, following a positive third-quarter report that surpassed analyst expectations. The company reported an adjusted EPS of 65 cents, outpacing the estimated 64 cents, and revenue grew by 5.2% year-over-year to $188.835 billion. Despite this growth, Walmart's weight-loss drug sales are facing a slowdown due to increased competition from prescription drugs.\n\nAnalysts have been optimistic about Walmart's future performance, raising their price forecasts and maintaining their existing ratings. Morgan Stanley's Simeon Gutman upgraded his rating to Overweight and increased his price target to $135 per share. Piper Sandler's Peter Keith also maintained an Overweight rating, raising his target to $138. Meanwhile, TD Cowen's Max Rakhlenko kept his Buy rating and boosted his forecast to $147, while Truist Securities' Scot Ciccarelli remained bullish with a Buy rating and a $134 price goal.\n\nBTIG's Robert Drbul reiterated his Buy rating and maintained a $140 price target, believing Walmart's U.S. business remains strong despite the impact of the health and wellness sector. He noted that Health & Wellness (H&W) is expected to drag reported comparable sales by roughly 125 basis points, but this is partly offset by a 60-basis-point contribution from GLP-1 drugs. Excluding H&W, Walmart's comparable sales have increased by 3.6%, showing improvement over previous quarters.\n\nThe analyst expects Walmart to continue driving healthy demand, although challenges remain in reported comparable sales due to H&W and potential pressure from Maximum Fair Price-related pharmacy deflation. Scot Ciccarelli expects Walmart's fiscal 2027 EPS to be around $2.90, with U.S. comparable sales growth slowing to 2.9%. He projects net sales of $748 billion for fiscal 2027, with operating income growth outpacing sales. For fiscal 2028, Ciccarelli raised his EPS estimate to $3.25.",
  "summary": "Walmart Inc. (NASDAQ:WMT) shares are recovering on Friday after declining on Thursday following its third-quarter results . It reported an adjusted EPS of 65 cents, exceeding analyst expectations of 64 cents. The figure excludes an after-tax loss of 3 cents per share related to equity and other investments. Revenue rose 5.2% year over year to $188.835 billion, topping the consensus estimate of…",
  "key_points": [
    "Walmart's Q3 earnings beat expectations with 65 cents adjusted EPS",
    "Analysts maintain bullish ratings, raising price targets to $134-$138",
    "Pharmacy deflation pressure expected to slow U.S. comparable sales"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}